TIROSINT-SOL (levothyroxine sodium) by Pfizer is synthesis. First approved in 2016.
Drug data last refreshed 12h ago · AI intelligence enriched 2d ago
TIROSINT-SOL is an oral liquid formulation of levothyroxine sodium, a synthetic thyroid hormone replacement used to treat hypothyroidism and other thyroid disorders. The drug works by diffusing into cell nuclei and binding to thyroid receptors, activating gene transcription and protein synthesis; approximately 80% of therapeutic T3 is derived from peripheral deiodination of T4. It represents a differentiated delivery platform for a well-established active pharmaceutical ingredient.
Product is in peak commercial phase with established market presence and modest Part D volume; team size and hiring activity likely stable but specialized.
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg
Worked on TIROSINT-SOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on TIROSINT-SOL offers exposure to specialty pharmaceutical commercialization within the stable endocrinology market, with emphasis on differentiated formulation positioning and patient access. Career trajectory is likely steady-state given peak lifecycle stage and minimal external competitive threats, providing stable but not high-growth opportunity.